Document:

EX-4.2

 Exhibit 4.2 

EXECUTION VERSION 

GENERATION BIO CO. 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

 

									
	 	 	 	 	 	  	Page	 
	1.	 	Definitions	  	 	1	 
			
	2.	 	Registration Rights	  	 	4	 
		 	2.1	 	Demand Registration	  	 	4	 
		 	2.2	 	Company Registration	  	 	6	 
		 	2.3	 	Underwriting Requirements	  	 	6	 
		 	2.4	 	Obligations of the Company	  	 	8	 
		 	2.5	 	Furnish Information	  	 	9	 
		 	2.6	 	Expenses of Registration	  	 	9	 
		 	2.7	 	Delay of Registration	  	 	10	 
		 	2.8	 	Indemnification	  	 	10	 
		 	2.9	 	Reports Under Exchange Act	  	 	12	 
		 	2.10	 	Limitations on Subsequent Registration Rights	  	 	13	 
		 	2.11	 	“Market Stand-off” Agreement	  	 	13	 
		 	2.12	 	Restrictions on Transfer	  	 	14	 
		 	2.13	 	Termination of Registration Rights	  	 	15	 
			
	3.	 	Information Rights	  	 	15	 
		 	3.1	 	Delivery of Financial Statements	  	 	15	 
		 	3.2	 	Inspection	  	 	16	 
		 	3.3	 	Termination of Information Rights	  	 	17	 
		 	3.4	 	Confidentiality	  	 	17	 
			
	4.	 	Rights to Future Stock Issuances	  	 	18	 
		 	4.1	 	Right of First Offer	  	 	18	 
		 	4.2	 	Termination	  	 	19	 
			
	5.	 	Additional Covenants	  	 	19	 
		 	5.1	 	Insurance	  	 	19	 
		 	5.2	 	Employee Agreements	  	 	19	 
		 	5.3	 	Employee Stock	  	 	19	 
		 	5.4	 	Board Matters	  	 	19	 
		 	5.5	 	Successor Indemnification	  	 	20	 
		 	5.6	 	Indemnification Matters	  	 	20	 
		 	5.7	 	Right to Conduct Activities	  	 	20	 
		 	5.8	 	Termination of Covenants	  	 	21	 
			
	6.	 	Miscellaneous	  	 	21	 
		 	6.1	 	Successors and Assigns	  	 	21	 
		 	6.2	 	Governing Law	  	 	22	 
		 	6.3	 	Counterparts	  	 	22	 
		 	6.4	 	Titles and Subtitles	  	 	22	 
		 	6.5	 	Notices	  	 	22	 

  
 i 

									
		 	6.6	 	Amendments and Waivers	  	 	22	 
		 	6.7	 	Severability	  	 	23	 
		 	6.8	 	Aggregation of Stock	  	 	23	 
		 	6.9	 	Additional Investors	  	 	23	 
		 	6.10	 	Entire Agreement	  	 	23	 
		 	6.11	 	Dispute Resolution	  	 	23	 
		 	6.12	 	Delays or Omissions	  	 	24	 

 Schedule A    - Schedule of Investors 

  
 ii 

 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 9th day of January,
2020, by and among Generation Bio Co., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an
“Investor”. 
 RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred
Stock (as defined below) and/or shares of the Company’s Series B Preferred Stock (as defined below) and possess registration rights, information rights, rights of first offer, and other rights pursuant to an Amended and Restated Investors’
Rights Agreement dated as of February 21, 2018, by and among the Company and such Investors (the “Prior Agreement”); and 

WHEREAS, the undersigned Existing Investors are holders of a majority of the Registrable Securities of the Company (as defined in the
Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; and 

WHEREAS, certain of the Investors are parties to that certain Series C Preferred Stock Purchase Agreement of even date herewith, by and
among the Company and certain of the Investors (the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations are conditioned upon the execution and delivery of this Agreement by such
Investors, Existing Investors holding a majority of the Registrable Securities and the Company. 
 NOW, THEREFORE, the parties hereby
agree as follows: 
 1.    Definitions. For purposes of this Agreement: 

1.1    “Affiliate” means, with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, limited partner, member, employee, officer or director of such Person or any venture capital
fund or other investment fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company or investment adviser with, such Person. For purposes of this definition, the
term “control” when used with respect to any Person means the power to direct the management or policies of such Person, directly or indirectly, whether through ownership of voting securities, by contract or otherwise, and the terms
“controlling” and “controlled” shall have meanings correlative to the foregoing. 

1.2    “Common Stock” means shares of the Company’s common stock, par value $0.0001 per share. 

1.3    “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may
become subject under the Securities Act, the Exchange Act, or other 

 
federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement
of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state
therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the
Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.4    “Derivative Securities” means any securities or rights convertible into, or exercisable or
exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

1.5    “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. 
 1.6    “Excluded Registration” means (i) a registration relating to the
sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include
substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable
upon conversion of debt securities that are also being registered. 
 1.7    “Fidelity” means
Fidelity Management & Research Company and its Affiliates that hold shares of Registrable Securities. 

1.8    “Form S-1” means such form under the Securities Act
as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.9    “Form S-3” means such form under the Securities Act
as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.10    “GAAP” means generally accepted accounting principles in the United States. 

1.11    “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.12    “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent,
spouse, sibling, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

  
 -2- 

 1.13    “Initiating Holders” means, collectively,
Holders who properly initiate a registration request under this Agreement. 
 1.14    “IPO” means the
Company’s first underwritten public offering of its Common Stock under the Securities Act. 
 1.15    “Key
Employee” means any executive-level employee (including, division director and vice president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company
Intellectual Property (as defined in the Purchase Agreement). 
 1.16    “Major Investor” means any
Investor that, individually or together with such Investor’s Affiliates, holds at least 875,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification
effected after the date hereof). 
 1.17    “New Securities” means, collectively, equity securities of
the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such
equity securities. 
 1.18    “Person” means any individual, corporation, partnership, trust, limited
liability company, association or other entity. 
 1.19    “Preferred Stock” means, collectively, shares
of the Company’s Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock. 

1.20    “Preferred Stock Directors” shall have the meaning given to such term in that certain Second
Amended and Restated Voting Agreement of even date herewith by and among the Company, the Investors and the other parties named therein, as may be amended and/or restated from time to time. 

1.21    “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of
the Preferred Stock, (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, held by the
Investors; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of,
the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned
pursuant to Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.22    “Registrable Securities then outstanding” means the number of shares determined by adding the
number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable
Securities. 

  
 -3- 

 1.23    “Restricted Securities” means the securities of
the Company required to be notated with the legend set forth in Subsection 2.12(b) hereof. 

1.24    “SEC” means the Securities and Exchange Commission. 

1.25    “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.26    “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.27    “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. 
 1.28    “Selling Expenses” means all underwriting discounts, selling
commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as
provided in Subsection 2.6. 
 1.29    “Series A Preferred Stock” means shares
of the Company’s Series A Preferred Stock, par value $0.0001 per share. 
 1.30    “Series B Preferred
Stock” means shares of the Company’s Series B Preferred Stock, par value $0.0001 per share. 

1.31    “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value
$0.0001 per share. 
 1.32    “T. Rowe Price” means T. Rowe Price Associates, Inc. and any successor or
affiliated registered investment advisor to the T. Rowe Price Investors. 
 1.33    “T. Rowe Price
Investors” means the Investors that are advisory or sub-advisory clients of T. Rowe Price with respect to holding shares of the Company. 

1.34    “Wellington” means Wellington Biomedical Innovation Master Investors (Cayman) I L.P. and its
permitted successors and assigns 
 1.35    “Wellington Investors” means Investors, or permitted
transferees of Registrable Securities held by Wellington Investors, that are advisory or subadvisory clients of Wellington Management Company LLP. 

2.    Registration Rights. The Company covenants and agrees as follows: 

2.1    Demand Registration. 

(a)    Form S-1 Demand. If at any time after the earlier of (i) five
(5) years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from holders of a majority of

  
 -4- 

 
the Registrable Securities then outstanding (the “Requisite Holders”) that the Company file a Form S-1 registration statement with
respect to at least forty percent (40%) of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of Selling Expenses, would exceed $10 million), then the Company shall (x) within ten
(10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after
the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be
registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is
given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(b)    Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty percent (20%) of the Registrable Securities then outstanding that the Company file a Form
S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5 million, then the
Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days
after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration
by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3.

 (c)    Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration
pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the
Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially
interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving
as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with
respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke
this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such ninety (90) day period other
than (i) pursuant to a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan, (ii) a registration on any form that does not include
substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities or (iii) or a registration in which the only Common Stock being registered is Common Stock
issuable upon conversion of debt securities that are also being registered. 

  
 -5- 

 (d)    The Company shall not be obligated to effect, or to take any
action to effect, any registration pursuant to Subsection 2.1(a)(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one
hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become
effective; (ii) after the Company has effected a registration pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Subsection 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a
Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected a registration pursuant
to Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d)
until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right
to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 

2.2    Company Registration. If the Company proposes to register (including, for this purpose, a registration
effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at
such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of
Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling
Expenses) of such withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 

2.3    Underwriting Requirements. 

(a)    If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the
Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the
Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in
such registration shall be conditioned upon such Holder’s participation in such 

  
 -6- 

 
underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such
underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other
provision of this Subsection 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating
Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of
Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders;
provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the
allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 

(b)    In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to
Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company
and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities,
requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the
Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If
the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders
in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in
accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of
Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the
offering be reduced below twenty percent (20%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination
described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership,
limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and
retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate
number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

  
 -7- 

 (c)    For purposes of Subsection 2.1, a
registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of Registrable
Securities that Holders have requested to be included in such registration statement are actually included. 

2.4    Obligations of the Company. Whenever required under this Section 2 to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its
commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period
of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be
extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any
registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day
period shall be extended for up to sixty (60) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b)    prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus
used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c)    furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as
required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d)    use its commercially reasonable efforts to register and qualify the securities covered by such registration
statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do
business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e)    in the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the underwriter(s) of such offering; 

  
 -8- 

 (f)    use its commercially reasonable efforts to cause all such
Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then
listed; 
 (g)    provide a transfer agent and registrar for all Registrable Securities registered pursuant to this
Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h)    promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any
disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of
the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or
advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i)    notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration
statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j)    after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the
Company amend or supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any
registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under
Rule 10b5-1 of the Exchange Act. 
 2.5    Furnish Information. It shall
be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such
information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6    Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with
registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the
reasonable fees and disbursements, not to exceed $25,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be
required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable
Securities to 

  
 -9- 

 
be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless
the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the
time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable
promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All
Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7    Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or
otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8    Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a)    To the extent permitted by law, the Company will indemnify and hold
harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel, accountants and investment advisers for each such Holder; any underwriter (as defined in the Securities Act) for each
such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that
the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent
shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on
behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 

(b)    To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless
the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any
underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such
Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such
selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any 

  
 -10- 

 
claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and
provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received
by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c)    Promptly after receipt by an indemnified party under this Subsection 2.8 of notice
of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the
indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure
materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Subsection 2.8. 
 (d)    To provide for just and equitable contribution to joint liability
under the Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by
the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that
this Subsection 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion
as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as
to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material
fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct
or prevent such statement or omission; provided, 

  
 -11- 

 
however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by
such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty
of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder
pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f)    Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public
offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and
otherwise shall survive the termination of this Agreement. 
 2.9    Reports Under Exchange Act. With a view to
making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 
 (a)    make and keep available adequate current public
information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b)    use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents
required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c)    furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to
the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the
IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form
S-3 (at any time after the Company so qualifies) and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any
such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies
to use such form). 

  
 -12- 

 2.10    Limitations on Subsequent Registration Rights. From and
after the date of this Agreement, the Company shall not, without the prior written consent of the Requisite Holders enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or
prospective holder (i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of
such securities will not reduce the number of the Registrable Securities of the Holders that are included or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective
holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9. 

2.11    “Market Stand-off” Agreement.
Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO and ending on the date specified by the Company and the
managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the IPO, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication
or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments
thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or
indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for the IPO or
(ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be
settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter
pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the
restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers, directors and stockholders individually owning more than one percent
(1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further
agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto.
In the event that the Company or the managing underwriter waives or terminates any of the restrictions contained in this Subsection 2.11 or in a lock-up agreement with any Holder,
officer, director or greater than one-percent stockholder of the Company (in any such case, the “Released Securities”), the restrictions contained in this
Subsection 2.11 and in any lock-up agreements executed by the Major Investors shall be waived or terminated, as applicable, to the same extent and with respect to the same percentage
of securities of each Major Investor as the percentage of Released Securities represent with respect to the securities held by the applicable Holder, officer, director or greater than one-percent stockholder.

  
 -13- 

 2.12    Restrictions on Transfer. 

(a)    The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the
Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure
compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144
to be bound by the terms of this Agreement. 
 (b)    Each certificate, instrument, or book entry representing
(i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger,
consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND
THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its
records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c)    The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with
the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction or,
following the IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and
circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose
legal opinion shall, be reasonably 

  
 -14- 

 
satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action”
letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any
other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such
Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action”
letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that, other than in
connection with a transaction in compliance with SEC Rule 144 following the IPO, each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry representing
the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144 or pursuant to an effective registration statement, the appropriate restrictive legend set forth in
Subsection 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in
order to establish compliance with any provisions of the Securities Act. 
 2.13    Termination of Registration
Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a)    the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of
Incorporation; 
 (b)    such time following the IPO as Rule 144 or another similar exemption under the Securities Act
is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; and 

(c)    the fourth (4th) anniversary of the IPO. 

3.    Information Rights. 

3.1    Delivery of Financial Statements. The Company shall deliver to each Major Investor: 

(a)    as soon as practicable, but in any event within one hundred fifty (150) days after the end of each fiscal year
of the Company, commencing with the fiscal year ending December 31, 2019 (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year and (iii) a statement of stockholders’ equity as
of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

(b)    as soon as practicable, but in any event within sixty (60) days after the end of each of the first three
(3) quarters of each fiscal year of the Company, unaudited 

  
 -15- 

 
statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial
statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c)    as soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each
fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable
upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but
reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company; 

(d)    as soon as practicable, but in any event before the end of each fiscal year, a budget and business plan for the
next fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after
prepared, any other budgets or revised budgets prepared by the Company; 
 (e)     such other information relating to
the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this
Subsection 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement in a form
acceptable to the Company) or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information
set forth in this Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it
must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the
Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 

3.2    Inspection. The Company shall permit each Major Investor (provided that the Board of Directors has not
reasonably determined that such Major Investor is a competitor of the Company), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s
affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably 

  
 -16- 

 
requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any
information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely
affect the attorney-client privilege between the Company and its counsel. 
 3.3    Termination of Information
Rights. The covenants set forth in Subsection 3.1 and 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first
becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event
occurs first; provided, however, that in the event the covenants set forth in Subsection 3.1 terminate upon a Deemed Liquidation Event, if the consideration received by the Investors in such Deemed Liquidation Event
includes securities that are not publicly traded (which, for the avoidance of doubt, shall not include contingent value rights), the Company will use commercially reasonable efforts to ensure that the Major Investors receive financial information
from the acquiring company or other successor to the Company comparable to those set forth in Section 3.1 of this Agreement. 

3.4    Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose,
divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement prior to the Company’s IPO (except with respect to information
furnished pursuant to Section 2 of this Agreement) (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public
in general (other than as a result of a breach of this Subsection 3.4 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or
(c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose
confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective
purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.4; (iii) to any Affiliate of such Investor in the ordinary course of
business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the
Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. Furthermore, nothing contained herein shall prevent any Investor or any person receiving confidential
information from an Investor in accordance with this Subsection 3.4 (each, a “Permitted Disclosee”) from entering into any business, entering into any agreement with a third party, or investing in or
engaging in investment discussions with any other company (whether or not competitive with the Company), provided that such Investor or Permitted Disclosee does not, except as permitted in accordance with this
Subsection 3.4, disclose any proprietary or confidential information of the Company in connection with such activities; and provided further, each Investor may identify the Company and the value of such Investor’s
security holdings in the Company in accordance with applicable investment reporting and disclosure regulations or internal policies and respond to routine examinations, demands, requests or reporting requirements of any regulator without prior
notice to or consent from the Company. 

  
 -17- 

 4.    Rights to Future Stock Issuances. 

4.1    Right of First Offer. Subject to the terms and conditions of this Subsection 4.1
and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby
granted to it, in such proportions as it deems appropriate, among itself and its Affiliates; provided that each such Affiliate (x) agrees to enter into this Agreement and each of (i) the Voting Agreement of even
date herewith by and among the Company, the Investors and the other parties named therein and (ii) the Right of First Refusal and Co-Sale Agreement of even date herewith by and among the Company, the
Investors and the other parties named therein, as an “Investor” under each such agreement and (y) agrees to purchase at least such number of New Securities as are allocable hereunder to the Major Investor holding the fewest
number of shares of Preferred Stock and any other Derivative Securities. 
 (a)    The Company shall give notice (the
“Offer Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it
proposes to offer such New Securities. 
 (b)    By notification to the Company within twenty (20) days after the
Offer Notice is given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the shares of Common Stock
issuable upon the conversion of the Preferred Stock then held by such Major Investor bears to the total number of shares of Common Stock issuable upon the conversion of all Preferred Stock of the Company then outstanding. At the expiration of such
twenty (20) day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to
do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified
above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable
(directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or
indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale
pursuant to this Subsection 4.1(b) shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c).

 (c)    If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided
in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and

  
 -18- 

 
sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the
Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be
deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this Subsection 4.1. 

(d)    The right of first offer in this Subsection 4.1 shall not be applicable to
(i) Exempted Securities (as defined in the Company’s Certificate of Incorporation) and (ii) shares of Common Stock issued in the IPO. 

4.2    Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no
further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act or (iii) upon a Deemed
Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 

5.    Additional Covenants. 

5.1    Insurance. The Company shall use its commercially reasonable efforts to obtain, within ninety (90) days
of the date hereof, from financially sound and reputable insurers, Directors and Officers liability insurance, in an amount and on terms and conditions satisfactory to the Board of Directors, and will use commercially reasonable efforts to cause
such insurance policies to be maintained until such time as the Board of Directors determines that such insurance should be discontinued. 

5.2    Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any
subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement; and
(ii) each Key Employee to enter into a noncompetition and nonsolicitation agreement, substantially in the form approved by the Board of Directors. 

5.3    Employee Stock. Unless otherwise approved by the Board of Directors, all future employees and consultants of
the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for
(i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly
installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in Subsection 2.11. In
addition, unless otherwise approved by the Board of Directors, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at cost
upon termination of employment of a holder of restricted stock. 
 5.4    Board Matters. Unless otherwise
determined by the vote of a majority of the directors then in office, the Board shall meet quarterly in accordance with an agreed-upon 

  
 -19- 

 
schedule. The Company shall reimburse each nonemployee directors for all reasonable out-of-pocket travel expenses
incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors or committees of the Board. Each Preferred Director shall be entitled in such person’s discretion to be a member of any
Board committee. Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., or their Affiliates (together, “Atlas”) shall appoint a Chair of the Board. 

5.5    Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges
into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the
obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation,
or elsewhere, as the case may be. 
 5.6    Indemnification Matters. The Company hereby acknowledges that one
(1) or more of the directors nominated to serve on the Board of Directors by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of
the Investors and certain of their Affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Fund Director are
primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of
expenses incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by
the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and, (c) that it
irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no
advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a
right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. 

5.7    Right to Conduct Activities. The Company hereby agrees and acknowledges that Atlas, Fidelity, Deerfield
Partners, L.P. (“Deerfield”), Casdin Partners Master Fund, L.P. and Casdin Venture Opportunities Fund, L.P. (together, “Casdin”), Foresite Capital Fund IV, LP (“Foresite”), Wellington, the
Wellington Investors, Harvard Management Private Equity Corporation (“Harvard”), Farallon Capital Management, L.L.C. and its Affiliates (collectively “Farallon”) and the T. Rowe Price Investors and their Affiliates
are professional investment funds, and as such invest in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently propose to be conducted). The Company
hereby agrees that, to the extent permitted under applicable law, no such Investor shall be liable to the Company for any claim arising out of, or based upon, (i) the 

  
 -20- 

 
investment by such Investor in any entity competitive with the Company or (ii) actions taken by any partner, officer or other representative of such Investor to assist any such competitive
company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not
relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any
liability associated with his or her fiduciary duties to the Company. Nothing in this Agreement shall preclude or create an obligation or duty restricting Atlas, Fidelity, Deerfield, Casdin, Foresite, Wellington, the Wellington Investors, Harvard,
Farallon, the T. Rowe Price Investors or T. Rowe Price from evaluating or purchasing securities, including publicly traded securities, of a particular enterprise, whether or not such enterprise has products or services which compete with those of
the Company. 
 5.8    Termination of Covenants. The covenants set forth in this Section 5, except for
Subsections 5.5, 5.6, and 5.7, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic
reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 

6.    Miscellaneous. 

6.1    Successors and Assigns. The rights under this Agreement may be assigned (but only with all related
obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or a trust for the benefit of an individual Holder or one or more of such
Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 600,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations) or,
if less, all of the Registrable Securities held by such Holder; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the
Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including
the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a
Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that
all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving
notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
herein. 

  
 -21- 

 6.2    Governing Law. This Agreement shall be governed by the
internal law of the State of Delaware. 
 6.3    Counterparts. This Agreement may be executed in two (2) or
more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying
with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4    Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to
be considered in construing or interpreting this Agreement. 
 6.5    Notices. All notices and other
communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by
electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day
delivery, with written verification of receipt. All communications shall be sent to the respective parties only at their addresses as set forth on Schedule A or Schedule B (as applicable) hereto,
or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with
this Subsection 6.5. If notice is given to the Company, a copy shall also be sent to Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, MA 02109, Attn: Stuart Falber. 

6.6    Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of (i) the Company and (ii) the Requisite Holders; provided that the Company may in its
sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.12(c)
shall be deemed to be a waiver); provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. The last sentence of Subsection 5.4 and
this sentence may not be amended without the prior written consent of Atlas; and provided further that Subsection 5.7 and this sentence may not be amended with respect to a particular Investor without the
prior written consent of such Investor. Notwithstanding the foregoing, (a) this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such
Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to
apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction; provided, that in the event of
any such waiver of the provisions of Section 4 with respect to a particular issuance of New Securities, if any of the Major 

  
 -22- 

 
Investors participate in such waiver and purchase securities in such particular offering then each Major Investor shall have the right to participate in such offering by purchasing up to that
portion of the New Securities which equals the proportion that the shares of Common Stock issuable upon the conversion of the Preferred Stock then held by such Major Investor bears to the total number of shares of Common Stock issuable upon the
conversion of all Preferred Stock of the Company then outstanding, on the same terms as such other stockholders) and (b) Subsections 3.1 and 3.2, Section 4 and any other section of this Agreement that is
only applicable to the Major Investors (including this clause (b) of this Subsection 6.6) may not be amended, modified, terminated or waived without the written consent of the holders of at least a majority of the Registrable Securities
then outstanding and held by the Major Investors. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any
amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term,
condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7    Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to
be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so
that it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.8    Aggregation of
Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as
among themselves in any manner they deem appropriate. 
 6.9    Additional Investors. Notwithstanding anything to
the contrary contained herein, if the Company issues additional shares of Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Preferred Stock may become a party to this
Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such
joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10    Entire Agreement. This Agreement (including any Schedules and Exhibits hereto), together with each
Management Rights Letter (as defined in the Purchase Agreement), constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject
matter hereof existing between the parties is expressly canceled. 
 6.11    Dispute Resolution. The parties
(a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware and to the jurisdiction of the federal district courts of Delaware for the purpose of any suit, action or other proceeding arising out of or
based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising 

  
 -23- 

 
out of or based upon this Agreement except in the state courts of Delaware or the federal district courts of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a
defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or
proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT,
THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND
THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY
EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND
VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 Each party will bear its own costs in respect of any
disputes arising under this Agreement. The prevailing party shall be entitled to reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. Each of the parties to this
Agreement consents to personal jurisdiction for any equitable action sought in a federal district court of Delaware or any court of the State of Delaware having subject matter jurisdiction. 

6.12    Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party
under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any
such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under
this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 [Remainder of Page Intentionally
Left Blank] 

  
 -24- 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	GENERATION BIO CO.
		
	By:	 	/s/ Geoffrey McDonough
	Name:	 	Geoffrey McDonough
	Title:	 	Chief Executive Officer

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	 T. ROWE PRICE NEW HORIZONS FUND, INC.

T. ROWE PRICE NEW HORIZONS TRUST
 T. ROWE PRICE U.S.
EQUITIES TRUST
 MASSMUTUAL SELECT FUNDS -

MASSMUTUAL SELECT T. ROWE PRICE
 SMALL AND MID CAP BLEND
FUND
 Each account, severally not jointly

	
	By: T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable
		
	By:	 	/s/ Franciso Alonso

 
			
	Name:	 	Franciso Alonso

 
			
	Title:	 	Vice President

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	 T. ROWE PRICE HEALTH SCIENCES FUND, INC.

TD MUTUAL FUNDS – TD HEALTH SCIENCES FUND
 VALIC
COMPANY I – HEALTH SCIENCES FUND
 T. ROWE PRICE HEALTH SCIENCES PORTFOLIO

Each account, severally not jointly

	
	By: T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable
		
	By:	 	/s/ John Hall
	Name:	 	John Hall
	Title:	 	Vice President

 SIGNATURE
PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	 T. ROWE PRICE SMALL-CAP STOCK FUND, INC.

T. ROWE PRICE INSTITUTIONAL SMALL-CAP STOCK FUND

T. ROWE PRICE SPECTRUM CONSERVATIVE ALLOCATION FUND
 T.
ROWE PRICE SPECTRUM MODERATE ALLOCATION FUND
 T. ROWE PRICE SPECTRUM MODERATE GROWTH ALLOCATION FUND

T. ROWE PRICE MODERATE ALLOCATION PORTFOLIO VALIC COMPANY I - SMALL CAP FUND

TD MUTUAL FUNDS - TD U.S. SMALL-CAP EQUITY FUND

T. ROWE PRICE U.S. SMALL-CAP CORE EQUITY TRUST U.S. SMALL-CAP STOCK TRUST
MINNESOTA LIFE INSURANCE COMPANY
 COSTCO 401(K) RETIREMENT PLAN

MASSMUTUAL SELECT FUNDS -
 MASSMUTUAL SELECT T. ROWE
PRICE SMALL AND MID CAP BLEND FUND

	Each account, severally not jointly
	
	By: T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable
		
	By:	 	/s/ Franciso Alonso

 
			
	Name:	 	Franciso Alonso

 
			
	Title:	 	Vice President

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	ATLAS VENTURE OPPORTUNITY FUND I, L.P.
		
	By:	 	/s/ Ommer Chohan

 
			
	Name:	 	Ommer Chohan

 
			
	Title:	 	Chief Financial Officer

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	 FIDELITY MT. VERNON STREET TRUST: 

FIDELITY SERIES GROWTH COMPANY FUND

		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIDELITY GROWTH COMPANY COMMINGLED POOL
	
	By: Fidelity Management Trust Company, as Trustee
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	 FIDELITY MT. VERNON STREET TRUST:

FIDELITY GROWTH COMPANY FUND

		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
			
	FIDELITY SECURITIES FUND: FIDELITY BLUE CHIP GROWTH FUND
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIDELITY BLUE CHIP GROWTH COMMINGLED POOL
	
	By: Fidelity Management Trust Company, as Trustee
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIAM TARGET DATE BLUE CHIP GROWTH COMMINGLED POOL
	
	By: Fidelity Institutional Asset Management Trust Company as Trustee
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIDELITY SECURITIES FUND: FIDELITY BLUE CHIP GROWTH K6 FUND
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
			
	FIDELITY SECURITIES FUND: FIDELITY SERIES CLUE CHIP GROWTH FUND
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIDELITY SECURITIES FUND: FIDELITY FLEX LARGE CAP GROWTH FUND
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIDELITY PURITAN TRUST: FIDELITY PURITAN FUND
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIDELITY CENTRAL INVESTMENT PORTFOLIOS LLC: FIDELITY HEALTH CARE CENTRAL FUND
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
			
	VARIABLE INSURANCE PRODUCTS FUND IV: HEALTH CARE PORTFOLIO
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIDELITY SELECT PORTFOLIOS: HEALTH CARE PORTFOLIO
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIDELITY ADVISOR SERIES VII: FIDELITY ADVISOR HEALTH CARE FUND
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIDELITY CONTRAFUND: FIDELITY CONTRAFUND
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
			
	FIDELITY CONTRAFUND: FIDELITY CONTRAFUND K6
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIDELITY CONTRAFUND COMMINGLED POOL
	
	By: Fidelity Management Trust Company, as Trustee
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIDELITY SELECT PORTFOLIOS: PHARMACEUTICALS PORTFOLIO
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

  

			
	FIDELITY BLUE CHIP GROWTH INSTITUTIONAL TRUST
	
	By: Its Manager Fidelity Investments Canada ULC
		
	By:	 	/s/ Colm Hogan

 
			
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
			
	FIDELITY MT. VERNON STREET TRUST: FIDELITY GROWTH COMPANY K6 FUND
		
	By:	 	/s/ Colm Hogan
	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	INVUS PUBLIC EQUITIES, LP
		
	By:	 	/s/ Raymond Debbane

 
			
	Name:	 	Raymond Debbane
	Title:	 	President of the General Partner

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	DEERFIELD PARTNERS, L.P.
	
	 By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

		
	By:	 	/s/ David J. Clark

 
			
	Name:	 	David J. Clark
	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	CASDIN VENTURE OPPORTUNITIES FUND, L.P.
	
	 By: Casdin Venture Opportunities Fund GP, LLC,

its General Partner

		
	By:	 	/s/ Eli Casdin

 
			
	Name:	 	Eli Casdin

 
			
	Title:	 	Managing Member

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	CASDIN PARTNERS MASTER FUND, L.P.
	
	By: Casdin Partners GP, LLC, its General Partner
		
	By:	 	/s/ Eli Casdin

 
			
	Name:	 	Eli Casdin

 
			
	Title:	 	Managing Member

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	FORESITE CAPITAL FUND IV, L.P.
	
	 By: Foresite Capital Management IV, LLC

Its: General Partner

		
	By:	 	/s/ Dennis D. Ryan

 
			
	Name:	 	Dennis D. Ryan
	Title:	 	Chief Financial Officer

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	LEERINK PARTNERS CO-INVESTMENT FUND, LLC
		
	By:	 	/s/ Joseph R. Gentile

 
			
	Name:	 	Joseph R. Gentile
	Title:	 	Manager

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	ZONE HEALTHCARE HOLDINGS, LLC
	
	By: Farallon Capital Management, L.L.C., its Manager
		
	By:	 	/s/ Philip Dreyfuss

 
			
	Name:	 	Philip Dreyfuss
	Title:	 	Managing Member

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P.
	
	/s/ Valerie N. Tipping
	By: Wellington Management Company LLP, as investment adviser
	Name:	 	Valerie N. Tipping
	Title:	 	Managing Director & Counsel

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
		
	By:	 	/s/ Julius Mercado

 
			
	Name:	 	Julius Mercado
	Title:	 	 Chief Operating Officer;
 Columbia Investment
Management
 Company, L.L.C.

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	HARVARD MANAGEMENT PRIVATE EQUITY CORPORATION
		
	By:	 	/s/ Elaine Chan

 
			
	Name:	 	Elaine Chan

 
			
	Title:	 	Authorized Signatory

 
			
		
	By:	 	/s/ Shashank Mathur

 
			
	Name:	 	Shashank Mathur

 
			
	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	GB CO-INVESTMENT LLC
		
	By:	 	/s/ Owen Littman

 
			
	Name:	 	Owen Littman
	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	/s/ Gustav Christensen
	Gustav Christensen

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	/s/ Arthur M. Krieg
	Arthur M. Krieg

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	/s/ Anthony Quinn
	Anthony Quinn

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	/s/ Charles Rowland
	Charles Rowland

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	PURCHASER:
	
	/s/ Catherine Stehman-Breen
	Catherine Stehman-Breen

 SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 SCHEDULE A 

Investors 
 T. Rowe Price Health
Sciences Fund, Inc. 
 T. Rowe Price Associates, Inc. 
 100
East Pratt Street 
 Baltimore, MD 21202 
 Attn: Andrew Baek,
Vice President 
 [**] 
 TD Mutual Funds - TD Health
Sciences Fund 
 T. Rowe Price Associates, Inc. 
 100 East
Pratt Street 
 Baltimore, MD 21202 
 Attn: Andrew Baek, Vice
President 
 [**] 
 VALIC Company I - Health Sciences Fund

 T. Rowe Price Associates, Inc. 
 100 East Pratt Street

 Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 
 T. Rowe Price Health Sciences Portfolio 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 
 T. Rowe Price New Horizons Fund, Inc. 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 

 T. Rowe Price New Horizons Trust 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 
 T. Rowe Price U.S. Equities Trust 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 
 MassMutual Select Funds - MassMutual Select 

T. Rowe Price Small and Mid Cap Blend Fund 
 T. Rowe Price
Associates, Inc. 
 100 East Pratt Street 
 Baltimore, MD 21202

 Attn: Andrew Baek, Vice President 
 [**] 

T. Rowe Price Small-Cap Stock Fund, Inc. 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 
 T. Rowe Price Institutional Small-Cap Stock Fund 
 T. Rowe Price Associates, Inc. 

100 East Pratt Street 
 Baltimore, MD 21202 

Attn: Andrew Baek, Vice President 
 [**] 

 T. Rowe Price Spectrum Conservative Allocation Fund 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 
 T. Rowe Price Spectrum Moderate Allocation Fund

 T. Rowe Price Associates, Inc. 
 100 East Pratt Street

 Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 
 T. Rowe Price Spectrum Moderate Growth Allocation Fund

 T. Rowe Price Associates, Inc. 
 100 East Pratt Street

 Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 
 T. Rowe Price Moderate Allocation Portfolio 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 
 U.S. Small-Cap
Stock Trust 
 T. Rowe Price Associates, Inc. 
 100 East
Pratt Street 
 Baltimore, MD 21202 
 Attn: Andrew Baek, Vice
President 
 [**] 

 VALIC Company I - Small Cap Fund 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 
 TD Mutual Funds - TD U.S. Small-Cap Equity Fund 
 T. Rowe Price Associates, Inc. 

100 East Pratt Street 
 Baltimore, MD 21202 

Attn: Andrew Baek, Vice President 
 [**] 

T. Rowe Price U.S. Small-Cap Core Equity Trust 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 
 Minnesota Life Insurance Company 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 
 Costco 401(k) Retirement Plan 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

[**] 

 Zone Healthcare Holdings, LLC 

c/o Farallon Capital Management, L.L.C. 
 One Maritime Plaza,
Suite 2100 
 San Francisco, CA 94111 
 Attn: Philip Dreyfuss

 [**] 
 Wellington Biomedical Innovation Master 

Investors (Cayman) I L.P. 
 c/o Wellington Management
Company LLP 
 Legal and Compliance 
 280 Congress Street 

Boston, MA 02210 
 [**] 

With a copy (which shall not constitute notice) to: 
 Cooley LLP

 500 Boylston Street, 14th Floor 
 Boston, MA 02116 

Attn: Joshua Rottner 
 [**] 

The Trustees of Columbia University 
 in the City of
New York 
 405 Lexington Ave. 63rd Floor 
 New York, NY
10174 
 Harvard Management Private Equity 

Corporation 
 600 Atlantic Avenue 

Boston, MA 02210 
 Attn: Elaine Chan / Emily Holden 

[**] 
 GB
Co-Investment LLC 
 599 Lexington Ave., 20th floor 

New York, NY 10022 
 Atlas Venture Opportunity Fund I, L.P.

 400 Technology Square 
 Cambridge, MA 02139 

 Atlas Venture Fund X, L.P. 

400 Technology Square 
 Cambridge, MA 02139 

Invus Public Equities, LP 
 750 Lexington Avenue, Floor 30

 New York, NY 10022 
 With copies to: 

The Invus Group LLC 
 750 Lexington Avenue 

New York, NY 10022 
 Attn: Philippe J. Amouyal 

Casdin Partners Master Fund, L.P. 
 1350 Avenue of the
Americas, Suite 2600 
 New York, New York 10019 
 Casdin
Venture Opportunities Fund, L.P. 
 1350 Avenue of the Americas, Suite 2600 

New York, New York 10019 
 Deerfield Partners, L.P. 

780 Third Avenue, 37th Floor 

New York, NY 10017 
 Attention: Lawrence Atinsky 

Fidelity Mt. Vernon Street Trust: Fidelity Series 

Growth Company Fund 
 State Street Bank & Trust

 P.O. Box 5756 
 Boston, Massachusetts 02206 

Attn: WAVELENGTH + CO Fidelity Mt. Vernon 
 Street Trust: Fidelity
Series Growth Company Fund 
 [**] 
 Fidelity Growth Company
Commingled Pool 
 Mag & Co. 
 c/o Brown Brothers
Harriman & Co. 
 Attn: Corporate Actions /Vault 
 140
Broadway 
 New York, NY 10005 
 [**] 

 Fidelity Mt. Vernon Street Trust: Fidelity 

Growth Company Fund 
 BNY Mellon 

Attn: Stacey Wolfe 
 525 William Penn Place Rm 0400 

Pittsburgh, PA 15259 
 [**] 

Fidelity Securities Fund: Fidelity Blue Chip 
 Growth
Fund 
 M.Gardiner & Co 
 c/o JPMorgan Chase Bank,
N.A 
 P.O. Box 35308 
 Newark, NJ 07101-8006 

[**] 
 Fidelity Blue Chip Growth Commingled Pool 

Mag & Co. 
 c/o Brown Brothers Harriman & Co.

 Attn: Corporate Actions /Vault 
 140 Broadway 

New York, NY 10005 
 [**] 

FIAM Target Date Blue Chip Growth 
 Commingled Pool

 State Street Bank & Trust 
 P.O. Box 5756 

Boston, Massachusetts 02206 
 Attn: FLAPPER CO fbo FIAM Target
Date Blue 
 Chip Growth Commingled Pool 
 [**] 

 Fidelity Securities Fund: Fidelity Blue Chip 

Growth K6 Fund 
 The Northern Trust Company 

Attn: Fidelity Client Team – GFS Custody, C-1N 

801 South Canal Street 
 Chicago, IL 60607 

Fidelity Securities Fund: Fidelity Blue Chip Growth K6 Fund 
 [**]

 Fidelity Securities Fund: Fidelity Series Blue Chip 

Growth Fund 
 State Street Bank & Trust 

PO Box 5756 
 Boston, Massachusetts 02206 

Attn: WAVECHART + CO fbo Fidelity Securities 
 Fund: Fidelity
Series Blue Chip Growth Fund 
 [**] 
 Fidelity Securities
Fund: Fidelity Flex Large Cap 
 Growth Fund 
 The
Northern Trust Company 
 Attn: Fidelity Client Team – GFS Custody, C-1N 

801 South Canal Street 
 Chicago, IL 60607 

Fidelity Securities Fund: Fidelity Flex Large Cap 
 Growth Fund

 [**] 
 Fidelity Puritan Trust: Fidelity Puritan Fund

 M.Gardiner & Co 
 c/o JPMorgan Chase Bank, N.A

 P.O. Box 35308 
 Newark, NJ 07101-8006 

[**] 

 Fidelity Central Investment Portfolios LLC: 

Fidelity Health Care Central Fund 
 M.Gardiner &
Co 
 c/o JPMorgan Chase Bank, N.A 
 P.O. Box 35308 

Newark, NJ 07101-8006 
 [**] 

Variable Insurance Products Fund IV: Health 
 Care
Portfolio 
 M.Gardiner & Co 
 c/o JPMorgan Chase
Bank, N.A 
 P.O. Box 35308 
 Newark, NJ 07101-8006 

[**] 
 Fidelity Select Portfolios: Health Care Portfolio

 Mag & Co. 
 c/o Brown Brothers
Harriman & Co. 
 Attn: Corporate Actions /Vault 
 140
Broadway 
 New York, NY 10005 
 [**] 

Fidelity Advisor Series VII: Fidelity Advisor 
 Health
Care Fund 
 M.Gardiner & Co 
 c/o JPMorgan Chase
Bank, N.A 
 P.O. Box 35308 
 Newark, NJ 07101-8006 

[**] 
 Fidelity Contrafund: Fidelity Contrafund 

Mag & Co. 
 c/o Brown Brothers Harriman & Co.

 Attn: Corporate Actions /Vault 
 140 Broadway 

New York, NY 10005 
 [**] 

 Fidelity Contrafund: Fidelity Contrafund K6 

The Northern Trust Company 
 Attn: Fidelity Client Team – GFS
Custody, C-1N 
 801 South Canal Street 

Chicago, IL 60607 
 Fidelity Contrafund: Fidelity Contrafund K6

 [**] 
 Fidelity Contrafund Commingled Pool 

Mag & Co. 
 c/o Brown Brothers Harriman & Co.

 Attn: Corporate Actions /Vault 
 140 Broadway 

New York, NY 10005 
 [**] 

Fidelity Select Portfolios: Pharmaceuticals Portfolio 

Mag & Co. 
 c/o Brown Brothers Harriman & Co.

 Attn: Corporate Actions /Vault 
 140 Broadway 

New York, NY 10005 
 [**] 

Fidelity Blue Chip Growth Institutional Trust 
 State
Street Bank & Trust 
 PO Box 5756 
 Boston,
Massachusetts 02206 
 Attn: Nominee fbo fund name 
 [**] 

Fidelity Mt. Vernon Street Trust: Fidelity Growth 

Company K6 Fund 
 BNY Mellon 

One Bny Mellon Center 
 500 Grant Street AIM 151-2700 
 Pittsburgh, PA 15258 

 Foresite Capital Fund IV, LP 

600 Montgomery Street, Suite 4500 
 San Francisco, CA 94111 

SVB Leerink Holdings LLC 
 One Federal Street, 37th Floor

 Boston, MA 02110 
 Attention: General Counsel 

Leerink Partners Co-Investment Fund, LLC 

One Federal Street, 37th Floor 
 Boston, MA 02110 

Attention: General Counsel 
 Gustav Christensen 

[**] 
 William Holodnak 

[**] 
 Geoffrey McDonough 

[**] 
 Don Nicholson 

[**] 
 Arthur M. Krieg 

[**] 
 Anthony Quinn 

[**] 
 Charles Rowland 

[**] 
 Catherine Stehman-Breen 

[**]EX-10.1

 Exhibit 10.1 

2017 STOCK INCENTIVE PLAN 

OF 

TORUS THERAPEUTICS, INC. 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	PAGE	 
	 1.
	 	 Purpose
	  	 	1	 
	 2.
	 	 Eligibility
	  	 	1	 
	 3.
	 	 Administration and Delegation
	  	 	1	 
	 (a)
	 	 Administration by the Board
	  	 	1	 
	 (b)
	 	 Appointment of Committees
	  	 	1	 
	 4.
	 	 Stock Available for Awards
	  	 	2	 
	 (a)
	 	 Number of Shares
	  	 	2	 
	 (b)
	 	 Substitute Awards
	  	 	2	 
	 5.
	 	 Stock Options
	  	 	2	 
	 (a)
	 	 General
	  	 	2	 
	 (b)
	 	 Incentive Stock Options
	  	 	2	 
	 (c)
	 	 Exercise Price.
	  	 	3	 
	 (d)
	 	 Duration of Options
	  	 	3	 
	 (e)
	 	 Exercise of Options
	  	 	3	 
	 (f)
	 	 Payment Upon Exercise
	  	 	3	 
	 6.
	 	 Stock Appreciation Rights
	  	 	4	 
	 (a)
	 	 General
	  	 	4	 
	 (b)
	 	 Measurement Price
	  	 	4	 
	 (c)
	 	 Duration of SARs
	  	 	5	 
	 (d)
	 	 Exercise of SARs
	  	 	5	 
	 7.
	 	 Restricted Stock; Restricted Stock Units
	  	 	5	 
	 (a)
	 	 General
	  	 	5	 
	 (b)
	 	 Terms and Conditions for All Restricted Stock Awards
	  	 	5	 
	 (c)
	 	 Additional Provisions Relating to Restricted Stock.
	  	 	5	 
	 (d)
	 	 Additional Provisions Relating to Restricted Stock Units
	  	 	6	 
	 8.
	 	 Other Stock-Based Awards
	  	 	6	 
	 (a)
	 	 General
	  	 	6	 
	 (b)
	 	 Terms and Conditions
	  	 	6	 
	 9.
	 	 Adjustments for Changes in Common Stock and Certain Other Events
	  	 	6	 
	 (a)
	 	 Changes in Capitalization
	  	 	6	 
	 (b)
	 	 Reorganization Events
	  	 	7	 
	 10.
	 	 General Provisions Applicable to Awards
	  	 	9	 
	 (a)
	 	 Transferability of Awards
	  	 	9	 
	 (b)
	 	 Documentation
	  	 	9	 
	 (c)
	 	 Board Discretion
	  	 	9	 
	 (d)
	 	 Termination of Status
	  	 	9	 
	 (e)
	 	 Withholding
	  	 	9	 
	 (f)
	 	 Amendment of Award.
	  	 	10	 
	 (g)
	 	 Conditions on Delivery of Stock.
	  	 	10	 
	 (h)
	 	 Acceleration
	  	 	11	 
	 11.
	 	 Miscellaneous
	  	 	11	 
	 (a)
	 	 No Right To Employment or Other Status
	  	 	11	 

							
	 	 	 	  	PAGE	 
	 (b)
	 	 No Rights As Stockholder
	  	 	11	 
	 (c)
	 	 Effective Date and Term of Plan
	  	 	11	 
	 (d)
	 	 Amendment of Plan
	  	 	11	 
	 (e)
	 	 Authorization of Sub-Plans (including Grants to non-U.S. Employees)
	  	 	11	 
	 (f)
	 	 Compliance with Section 409A of the Code
	  	 	12	 
	 (g)
	 	 Limitations on Liability
	  	 	12	 
	 (h)
	 	 Governing Law
	  	 	12	 

  
 - ii - 

 2017 STOCK INCENTIVE PLAN 

OF 

TORUS THERAPEUTICS, INC. 

 

	1.	 Purpose 

The purpose of this 2017 Stock Incentive Plan (the “Plan”) of Torus Therapeutics, Inc., a Delaware corporation (the
“Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by
providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except where the context otherwise requires,
the term “Company” shall include any of the Company’s present and future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue Code of 1986, as amended, and any regulations
thereunder (the “Code”) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the
Company (the “Board”); provided, however, that such other business ventures shall be limited to entities that, where required by Section 409A of the Code, are eligible issuers of service recipient stock (as
defined in Treas. Reg. Section 1.409A-1(b)(5)(iii)(E), or applicable successor regulation). 
  

	2.	 Eligibility 

All of the Company’s employees, officers and directors, as well as consultants and advisors to the Company (as such terms consultants and
advisors are defined and interpreted for purposes of Rule 701 under the Securities Act of 1933, as amended (the “Securities Act”) (or any successor rule)) are eligible to be granted Awards under the Plan. Each person who is granted
an Award under the Plan is deemed a “Participant.” “Award” means Options (as defined in Section 5), SARs (as defined in Section 6), Restricted Stock (as defined in Section 7), Restricted Stock Units
(as defined in Section 7) and Other Stock-Based Awards (as defined in Section 8). 
  

	3.	 Administration and Delegation 

(a)    Administration by the Board. The Plan will be administered by the Board. The Board shall have authority to
grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe and interpret the terms of the Plan and any Award agreements entered into under
the Plan. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the sole and final judge of
such expediency. All actions and decisions by the Board with respect to the Plan and any Awards shall be made in the Board’s discretion and shall be final and binding on all Participants and any other persons having or claiming any interest in
the Plan or in any Award. 
 (b)    Appointment of Committees. To the extent permitted by applicable law, the
Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (each, a “Committee”). All references in the Plan to the “Board” shall mean the Board or a Committee
to the extent that the Board’s powers or authority under the Plan have been delegated to such Committee. 

	4.	 Stock Available for Awards 

(a)    Number of Shares. Subject to adjustment under Section 9, Awards may be made under the Plan for up to
5,424,000 shares of common stock, $0.0001 par value per share, of the Company (the “Common Stock”), any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)). If any Award expires or
is terminated, surrendered or canceled without having been fully exercised, is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price
pursuant to a contractual repurchase right), or results in any Common Stock not being issued, the unused Common Stock subject to such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to
the Company by a Participant to exercise an Award or to satisfy tax withholding obligations arising with respect to an Award shall be added to the number of shares of Common Stock available for the grant of Awards under the Plan. However, in the
case of Incentive Stock Options, the two immediately preceding sentences shall be subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares. 

(b)    Substitute Awards. In connection with a merger or consolidation of an entity with the Company or the
acquisition by the Company of property or stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted by such entity or an affiliate thereof. Substitute Awards may be granted on such
terms as the Board deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in Section 4(a), except as may be required
by reason of Section 422 and related provisions of the Code. 
  

	5.	 Stock Options 

(a)    General. The Board may grant options to purchase Common Stock (each, an “Option”) and
determine the number of shares of Common Stock to be subject to each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to applicable federal or state
securities laws, as it considers necessary or advisable. 
 (b)    Incentive Stock Options. An Option that the
Board intends to be an “incentive stock option” as defined in Section 422 of the Code (an “Incentive Stock Option”) shall only be granted to employees of Torus Therapeutics, Inc., any of Torus Therapeutics,
Inc.’s present and future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Code, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code, and shall be
subject to and shall be construed consistently with the requirements of Section 422 of the Code. An Option that is not intended to be an Incentive Stock Option shall be designated non-statutory stock
option (a “Nonstatutory Stock Option).” The Company shall have no liability to a Participant, or any other person, if an Option (or any part thereof) that is intended to be an Incentive Stock Option is not an Incentive Stock
Option or if the Company converts an Incentive Stock Option to a Nonstatutory Stock Option. 

  
 - 2 - 

 (c)    Exercise Price. The Board shall establish the exercise
price of each Option and specify the exercise price in the applicable Option agreement. The exercise price shall be not less than 100% of the Grant Date Fair Market Value (as defined below) of the Common Stock on the date the Option is granted;
provided that if the Board approves the grant of an Option with an exercise price to be determined on a future date, the exercise price shall not be less than 100% of the Grant Date Fair Market Value on such future date. The “Grant Date Fair
Market Value” of a share of Common Stock for purposes of the Plan will be determined as follows: 
 (1)    if
the Common Stock is not publicly traded, the Board will determine the Fair Market Value for purposes of the Plan using any measure of value it determines to be appropriate (including, as it considers appropriate, relying on appraisals) in a manner
consistent with the valuation principles under Code Section 409A, except as the Board may expressly determine otherwise; 

(2)    if the Common Stock is listed on a national securities exchange, the closing sale price (for the primary trading
session) on the date of grant; or 
 (3)    if the Common Stock is not listed on any such exchange, the average of the
closing bid and asked prices as reported by an authorized OTCBB market data vendor as listed on the OTCBB website (otcbb.com) on the date of grant. 

For any date that is not a trading day, the Grant Date Fair Market Value of a share of Common Stock for such date will be determined by using
the closing sale price or average of the bid and asked prices, as appropriate, for the immediately preceding trading day and with the timing in the formulas above adjusted accordingly. The Board can substitute a particular time of day or other
measure of “closing sale price” or “bid and asked prices” if appropriate because of exchange or market procedures or can, in its discretion, use weighted averages either on a daily basis or such longer period as complies with
Code Section 409A. 
 The Board has discretion to determine the Grant Date Fair Market Value for purposes of the Plan, and all Awards
are conditioned on the applicable Participant’s agreement that the Board’s determination is conclusive and binding even though others might make a different determination. 

(d)    Duration of Options. Each Option shall be exercisable at such times and subject to such terms and conditions
as the Board may specify in the applicable option agreement; provided, however, that no Option will be granted with a term in excess of 10 years. 

(e)    Exercise of Options. Options may be exercised by delivery to the Company of a notice of exercise in a form
of notice (which may be electronic) approved by the Company, together with payment in full (in the manner specified in Section 5(f)) of the exercise price for the number of shares for which the Option is exercised. Shares of Common Stock
subject to the Option will be delivered by the Company as soon as practicable following exercise. 

  
 - 3 - 

 (f)    Payment Upon Exercise. Common Stock purchased upon the
exercise of an Option granted under the Plan shall be paid for as follows: 
 (1)    in cash or by check, payable to the
order of the Company; 
 (2)    when the Common Stock is registered under the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), except as may otherwise be provided in the applicable Option agreement or approved by the Board, in its discretion, by (i) delivery of an irrevocable and unconditional undertaking by a creditworthy broker
to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker
to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding; 

(3)    when the Common Stock is registered under the Exchange Act and to the extent provided for in the applicable Option
agreement or approved by the Board, in its discretion, by delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their fair market value (valued in the manner determined by (or in a manner
approved by) the Board), provided (i) such method of payment is then permitted under applicable law, (ii) such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum period of time, if
any, as may be established by the Board in its discretion and (iii) such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements; 

(4)    to the extent provided for in the applicable Nonstatutory Stock Option agreement or approved by the Board in its
discretion, by delivery of a notice of “net exercise” to the Company, as a result of which the Participant would receive (i) the number of shares underlying the portion of the Option being exercised, less (ii) such number of
shares as is equal to (A) the aggregate exercise price for the portion of the Option being exercised divided by (B) the fair market value of the Common Stock (valued in the manner determined by (or in a manner approved by) the Board) on
the date of exercise; 
 (5)    to the extent permitted by applicable law and provided for in the applicable Option
agreement or approved by the Board, in its discretion, by (i) delivery of a promissory note of the Participant to the Company on terms determined by the Board, or (ii) payment of such other lawful consideration as the Board may determine;
or 
 (6)    by any combination of the above permitted forms of payment. 

 

	6.	 Stock Appreciation Rights 

(a)    General. The Board may grant Awards consisting of stock appreciation rights (“SARs”)
entitling the Participant, upon exercise, to receive an amount of Common Stock or cash or a combination thereof (such form to be determined by the Board) determined by reference to appreciation, from and after the date of grant, in the fair market
value of a share of Common Stock (valued in the manner determined by (or in a manner approved by) the Board) over the measurement price established pursuant to Section 6(b). The date as of which such appreciation is determined shall be the
exercise date. 
 (b)    Measurement Price. The Board shall establish the measurement price of each SAR and
specify it in the applicable SAR agreement. The measurement price shall not be less than 

  
 - 4 - 

 
100% of the Grant Date Fair Market Value of a share of Common Stock on the date the SAR is granted; provided, that if the Board approves the grant of an SAR effective as of a future date,
the measurement price shall not be less than 100% of the Grant Date Fair Market Value on such future date. 

(c)    Duration of SARs. Each SAR shall be exercisable at such times and subject to such terms and conditions as
the Board may specify in the applicable SAR agreement; provided, however, that no SAR will be granted with a term in excess of 10 years. 

(d)    Exercise of SARs. SARs may be exercised by delivery to the Company of a notice of exercise in a form (which
may be electronic) approved by the Company, together with any other documents required by the Board. 
  

	7.	 Restricted Stock; Restricted Stock Units 

(a)    General. The Board may grant Awards entitling Participants to acquire shares of Common Stock
(“Restricted Stock”), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the
Participant in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. The Board may also grant Awards
entitling the Participant to receive shares of Common Stock or cash to be delivered at the time such Award vests (“Restricted Stock Units”) (Restricted Stock and Restricted Stock Units are each referred to herein as a
“Restricted Stock Award”). 
 (b)    Terms and Conditions for All Restricted Stock Awards. The
Board shall determine the terms and conditions of a Restricted Stock Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any. 

(c)    Additional Provisions Relating to Restricted Stock. 

(1)    Dividends. Unless otherwise provided in the applicable Award agreement, any dividends (whether paid in cash,
stock or property) declared and paid by the Company with respect to shares of Restricted Stock (“Accrued Dividends”) shall be paid to the Participant only if and when such shares become free from the restrictions on transferability
and forfeitability that apply to such shares. Each payment of Accrued Dividends will be made no later than the end of the calendar year in which the dividends are paid to stockholders of that class of stock or, if later, the 15th day of the third
month following the lapsing of the restrictions on transferability and the forfeitability provisions applicable to the underlying shares of Restricted Stock. 

(2)    Stock Certificates. The Company may require that any stock certificates issued in respect of shares of
Restricted Stock, as well as dividends or distributions paid on such Restricted Stock, shall be deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). At the expiration of the
applicable restriction periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to Participant’s Designated Beneficiary. “Designated
Beneficiary” means (i) the beneficiary designated, in a manner determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant’s death or (ii) in the
absence of an effective designation by a Participant, “Designated Beneficiary” means the Participant’s estate. 

  
 - 5 - 

 (d)     Additional Provisions Relating to Restricted Stock Units.

 (1)    Settlement. Upon the vesting of and/or lapsing of any other restrictions (i.e., settlement) with
respect to each Restricted Stock Unit, the Participant shall be entitled to receive from the Company the number of shares of Common Stock specified in the Award agreement or (if so provided in the applicable Award agreement or otherwise determined
by the Board) an amount of cash equal to the fair market value (valued in the manner determined by (or in a manner approved by) the Board) of such number of shares of Common Stock or a combination thereof. The Board may, in its discretion, provide
that settlement of Restricted Stock Units shall be deferred, on a mandatory basis or at the election of the Participant in a manner that complies with Section 409A of the Code. 

(2)    Voting Rights. A Participant shall have no voting rights with respect to any Restricted Stock Units. 

(3)    Dividend Equivalents. The Award agreement for Restricted Stock Units may provide Participants with the right
to receive an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of Common Stock (“Dividend Equivalents”). Dividend Equivalents may be paid currently or credited to an
account for the Participants, may be settled in cash and/or shares of Common Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which paid, in each case to the extent
provided in the applicable Award agreement. 
  

	8.	 Other Stock-Based Awards 

(a)    General. The Board may grant other Awards of shares of Common Stock, and other Awards that are valued in
whole or in part by reference to, or are otherwise based on, shares of Common Stock or other property (“Other Stock-Based Awards”). Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of
other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall determine. 

(b)    Terms and Conditions. Subject to the provisions of the Plan, the Board shall determine the terms and
conditions of each Other Stock-Based Award, including any purchase price applicable thereto. 
  

	9.	 Adjustments for Changes in Common Stock and Certain Other Events 

(a)    Changes in Capitalization. In the event of any stock split, reverse stock split, stock dividend,
recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an
ordinary cash dividend, (i) the number and class of securities available under the Plan, (ii) the number and class of securities and exercise price per share of each outstanding Option, (iii) the share and per-share provisions and the measurement price of each outstanding 

  
 - 6 - 

 
SAR, (iv) the number of shares subject to and the repurchase price per share subject to each outstanding Award of Restricted Stock and (v) the share and
per-share-related provisions and the purchase price, if any, of each outstanding Award of Restricted Stock Unit and each outstanding Other Stock-Based Award, shall be equitably adjusted by the Company (or
substituted Awards may be made, if applicable) in the manner determined by the Board. Without limiting the generality of the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price
of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then an optionee who exercises an Option between the record date and
the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were
not outstanding as of the close of business on the record date for such stock dividend. 
 (b)    Reorganization
Events. 
 (1)    Definition. A “Reorganization Event” shall mean: (a) any merger or
consolidation of the Company with or into another entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b) any transfer or
disposition of all of the Common Stock of the Company for cash, securities or other property pursuant to a share exchange or other transaction or (c) any liquidation or dissolution of the Company. 

(2)    Consequences of a Reorganization Event on Awards Other than Restricted Stock. 

(i)    In connection with a Reorganization Event, the Board may take any one or more of the following actions as to all
or any (or any portion of) outstanding Awards other than Restricted Stock on such terms as the Board determines (except to the extent specifically provided otherwise in an applicable Award agreement or another agreement between the Company and the
Participant): (i) provide that such Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii) upon written notice to a Participant, provide that all
of the Participant’s unexercised and/or unvested Awards will terminate immediately prior to the consummation of such Reorganization Event unless exercised by the Participant (to the extent then exercisable) within a specified period following
the date of such notice, (iii) provide that outstanding Awards shall become exercisable, realizable, or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event,
(iv) in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the “Acquisition Price”), make
or provide for a cash payment to Participants with respect to each Award held by a Participant equal to (A) the number of shares of Common Stock subject to the vested portion of the Award (after giving effect to any acceleration of vesting that
occurs upon or immediately prior to such Reorganization Event) multiplied by (B) the excess, if any, of (I) the Acquisition Price over (II) the exercise, measurement or purchase price of such Award and any applicable tax withholdings,
in exchange for the termination of such Award, (v) provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, 

  
 - 7 - 

 
net of the exercise, measurement or purchase price thereof and any applicable tax withholdings) and (vi) any combination of the foregoing. In taking any of the actions permitted under this
Section 9(b)(2), the Board shall not be obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically. 

(ii)    Notwithstanding the terms of Section 9(b)(2)(i), in the case of outstanding Restricted Stock Units that are
subject to Section 409A of the Code: (i) if the applicable Restricted Stock Unit agreement provides that the Restricted Stock Units shall be settled upon a “change in control event” within the meaning of Treasury Regulation
Section 1.409A- 3(i)(5)(i), and the Reorganization Event constitutes such a “change in control event”, then no assumption or substitution shall be permitted pursuant to Section 9(b)(2)(i) and the Restricted Stock Units shall
instead be settled in accordance with the terms of the applicable Restricted Stock Unit agreement; and (ii) the Board may only undertake the actions set forth in clauses (iii), (iv) or (v) of Section 9(b)(2)(i) if the Reorganization Event
constitutes a “change in control event” as defined under Treasury Regulation Section 1.409A-3(i)(5)(i) and such action is permitted or required by Section 409A of the Code; if the
Reorganization Event is not a “change in control event” as so defined or such action is not permitted or required by Section 409A of the Code, and the acquiring or succeeding corporation does not assume or substitute the Restricted
Stock Units pursuant to clause (i) of Section 9(b)(2)(i), then the unvested Restricted Stock Units shall terminate immediately prior to the consummation of the Reorganization Event without any payment in exchange therefor. 

(iii)    For purposes of Section 9(b)(2)(i), an Award (other than Restricted Stock) shall be considered assumed if,
following consummation of the Reorganization Event, such Award confers the right to purchase or receive pursuant to the terms of such Award, for each share of Common Stock subject to the Award immediately prior to the consummation of the
Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the
Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if the consideration received as a
result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be
received upon the exercise or settlement of the Award to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determined to be equivalent in value (as of the date
of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event. 

(3)    Consequences of a Reorganization Event on Restricted Stock. Upon the occurrence of a Reorganization Event
other than a liquidation or dissolution of the Company, the repurchase and other rights of the Company with respect to outstanding Restricted Stock shall inure to the benefit of the Company’s successor and shall, unless the Board determines
otherwise, apply to the cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as they applied to such Restricted Stock;
provided, however, that the Board may provide for 

  
 - 8 - 

 
termination or deemed satisfaction of such repurchase or other rights under the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, either
initially or by amendment, or provide for forfeiture of such Restricted Stock if issued at no cost. Upon the occurrence of a Reorganization Event involving the liquidation or dissolution of the Company, except to the extent specifically provided to
the contrary in the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, all restrictions and conditions on all Restricted Stock then outstanding shall automatically be deemed terminated or
satisfied. 
  

	10.	 General Provisions Applicable to Awards. 

(a)    Transferability of Awards. Awards (or any interest in an Award, including, prior to exercise, any interest
in shares of Common Stock issuable upon exercise of an Option or SAR) shall not be sold, assigned, transferred (including by establishing any short position, put equivalent position (as defined in Rule 16a-1
issued under the Exchange Act) or call equivalent position (as defined in Rule 16a-1 issued under the Exchange Act)), pledged, hypothecated or otherwise encumbered by the person to whom they are granted,
either voluntarily or by operation of law, and, during the life of the Participant, shall be exercisable only by the Participant; except that Awards, other than Awards subject to Section 409A of the Code, may be transferred to family members
(as defined in Rule 701(c)(3) under the Securities Act) through gifts or (other than Incentive Stock Options) domestic relations orders or to an executor or guardian upon the death or disability of the Participant. The Company shall not be required
to recognize any such permitted transfer until such time as such permitted transferee shall deliver to the Company a written instrument, as a condition to such transfer, in form and substance satisfactory to the Company confirming that such
transferee shall be bound by all of the terms and conditions of the Award. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees. For the avoidance of doubt, nothing contained in this
Section 10(a) shall be deemed to restrict a transfer to the Company. 
 (b)    Documentation. Each Award
shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each Award may contain terms and conditions in addition to those set forth in the Plan. 

(c)    Board Discretion. Except as otherwise provided by the Plan, each Award may be made alone or in addition or
in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly. 

(d)    Termination of Status. The Board shall determine the effect on an Award of the disability, death,
termination or other cessation of employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant’s legal
representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Award. 

(e)    Withholding. The Participant must satisfy all applicable federal, state, and local or other income and
employment tax withholding obligations before the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award. The Company may elect to satisfy the withholding obligations through additional withholding on
salary or wages. 

  
 - 9 - 

 
If the Company elects not to or cannot withhold from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a broker tender to the
Company cash equal to the withholding obligations. Payment of withholding obligations is due before the Company will issue any shares on exercise, vesting or release from forfeiture of an Award or at the same time as payment of the exercise or
purchase price unless the Company determines otherwise. If provided for in an Award or approved by the Board in its discretion, a Participant may satisfy such tax obligations in whole or in part by delivery (either by actual delivery or attestation)
of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their fair market value (valued in the manner determined by (or in a manner approved by) the Company); provided, however, except as
otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company’s minimum statutory withholding obligations (based on minimum statutory withholding rates for
federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income), except that, to the extent that the Company is able to retain shares of Common Stock having a fair market value (valued in the
manner determined by (or in a manner approved by) the Company) that exceeds the statutory minimum applicable withholding tax without financial accounting implications or the Company is withholding in a jurisdiction that does not have a statutory
minimum withholding tax, the Company may retain such number of shares of Common Stock (up to the number of shares having a fair market value (valued in the manner determined by (or in a manner approved by) the Company) equal to the maximum
individual statutory rate of tax) as the Company shall determine in its discretion to satisfy the tax liability associated with any Award. Shares used to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture,
unfulfilled vesting or other similar requirements. 
 (f)    Amendment of Award. 

(1)    The Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor
another Award of the same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option. The Participant’s consent to such action shall be required unless (i) the
Board determines that the action, taking into account any related action, does not materially and adversely affect the Participant’s rights under the Plan or (ii) the change is permitted under Section 9. 

(2)    The Board may, without stockholder approval, amend any outstanding Award granted under the Plan to provide an
exercise price per share that is lower than the then-current exercise price per share of such outstanding Award. The Board may also, without stockholder approval, cancel any outstanding award (whether or not granted under the Plan) and grant in
substitution therefor new Awards under the Plan covering the same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled award. 

(g)    Conditions on Delivery of Stock. The Company will not be obligated to deliver any shares of Common Stock
pursuant to the Plan or to remove restrictions from shares previously issued or delivered under the Plan until (i) all conditions of the Award have been met or removed to the satisfaction of the Company, (ii) in the opinion of the
Company’s counsel, all other legal 

  
 - 10 - 

 
matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock market
rules and regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. 

(h)    Acceleration. The Board may at any time provide that any Award shall become immediately exercisable in whole
or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. 
  

	11.	 Miscellaneous. 

(a)    No Right To Employment or Other Status. No person shall have any claim or right to be granted an Award by
virtue of the adoption of the Plan, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to
dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan, except as expressly provided in the applicable Award. 

(b)    No Rights As Stockholder. Subject to the provisions of the applicable Award, no Participant or Designated
Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder of such shares. 

(c)    Effective Date and Term of Plan. The Plan shall become effective on the date on which it is adopted by the
Board. No Awards shall be granted under the Plan after the expiration of 10 years from the earlier of (i) the date on which the Plan was adopted by the Board or (ii) the date the Plan was approved by the Company’s stockholders, but
Awards previously granted may extend beyond that date. 
 (d)    Amendment of Plan. The Board may amend, suspend
or terminate the Plan or any portion thereof at any time; provided that if at any time the approval of the Company’s stockholders is required as to any modification or amendment under Section 422 of the Code or any successor
provision with respect to Incentive Stock Options, the Board may not effect such modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance with this
Section 11(d) shall apply to, and be binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, provided the Board determines that such amendment, taking into account any related action, does not
materially and adversely affect the rights of Participants under the Plan. 
 (e)    Authorization of Sub-Plans (including Grants to non-U.S. Employees). The Board may from time to time establish one or more sub-plans under the Plan
for purposes of satisfying applicable securities, tax or other laws of various jurisdictions. The Board shall establish such sub-plans by adopting supplements to the Plan containing (i) such limitations
on the Board’s discretion under the Plan as the Board deems necessary or desirable or (ii) such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements
adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any
jurisdiction which is not the subject of such supplement. 

  
 - 11 - 

 (f)    Compliance with Section 409A of the Code. If and to
the extent (i) any portion of any payment, compensation or other benefit provided to a Participant pursuant to the Plan in connection with Participant’s employment termination constitutes “nonqualified deferred compensation”
within the meaning of Section 409A of the Code and (ii) the Participant is a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code, in each case as determined by the Company in accordance with its procedures, by which
determinations the Participant (through accepting the Award) agrees that the Participant is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six months plus one day after the date of
“separation from service” (as determined under Section 409A of the Code) (the “New Payment Date”), except as Section 409A of the Code may then permit. The aggregate of any payments that otherwise would have been
paid to the Participant during the period between the date of separation from service and the New Payment Date shall be paid to the Participant in a lump sum on such New Payment Date, and any remaining payments will be paid on their original
schedule. 
 The Company makes no representations or warranty and shall have no liability to the Participant or any other person if any provisions of or
payments, compensation or other benefits under the Plan are determined to constitute nonqualified deferred compensation subject to Section 409A of the Code but do not to satisfy the conditions of that section. 

(g)    Limitations on Liability. Notwithstanding any other provisions of the Plan, no individual acting as a
director, officer, other employee, or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan, nor will such
individual be personally liable with respect to the Plan because of any contract or other instrument such individual executes in such individual’s capacity as a director, officer, other employee, or agent of the Company. The Company will
indemnify and hold harmless each director, officer, other employee, or agent of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been or will be delegated, against any cost or expense (including
attorneys’ fees) or liability (including any sum paid in settlement of a claim with the Board’s approval) arising out of any act or omission to act concerning the Plan unless arising out of such person’s own fraud or bad faith. 

(h)    Governing Law. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted
in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a
jurisdiction other than the State of Delaware. 
 * * * * 

  
 - 12 - 

 TORUS THERAPEUTICS, INC., 

2017 STOCK INCENTIVE PLAN 

CALIFORNIA SUPPLEMENT 

Pursuant to Section 11(e) of the Plan, the Board has adopted this supplement for purposes of satisfying the requirements of
Section 25102(o) of the California Law: 
 Any Awards granted under the Plan to a Participant who is a resident of the State of
California on the date of grant (a “California Participant”) shall be subject to the following additional limitations, terms and conditions: 
  

	1.	 Additional Limitations on Options. 

(a)    Maximum Duration of Options. No Options granted to California Participants shall have a term in excess of 10
years measured from the Option grant date. 
 (b)    Minimum Exercise Period Following Termination. Unless a
California Participant’s employment is terminated for cause (as defined by applicable law, the terms of the Plan or option grant or a contract of employment), in the event of termination of employment of such Participant, such Participant shall
have the right to exercise an Option, to the extent that such Participant is entitled to exercise such Option on the date employment terminated, until the earlier of: (i) at least six months from the date of termination, if termination was
caused by such Participant’s death or disability, (ii) at least 30 days from the date of termination, if termination was caused other than by such Participant’s death or disability and (iii) the Option expiration date. 

2.    Additional Limitations for Other Stock-Based Awards. The terms of all Awards granted to a California Participant under
Section 8 of the Plan shall comply, to the extent applicable, with Section 260.140.46 of the California Code of Regulations. 

3.    Additional Limitations on Timing of Awards. No Award granted to a California Participant shall become exercisable, vested or
realizable, as applicable to such Award, unless the Plan has been approved by the holders of a majority of the Company’s outstanding voting securities by the later of (i) within 12 months before or after the date the Plan was adopted by
the Board, or (ii) prior to or within 12 months of the granting of any Award to a California Participant. 
 4.    Additional
Restriction Regarding Recapitalizations, Stock Splits, Etc. For purposes of Section 9 of the Plan, in the event of a stock split, reverse stock split, stock dividend, recapitalization, combination, reclassification or other distribution of
the Company’s securities underlying the Award without the receipt of consideration by the Company, the number of securities purchasable, and in the case of Options, the exercise price of such Options, shall be proportionately adjusted. 

5.    Additional Limitations on Transferability of Awards. Notwithstanding the provisions of Section 10(a) of the Plan, an
Award granted to a California Participant may not be transferred to an executor or guardian upon the disability of the Participant. 
 * * *
* 

 Torus Therapeutics, Inc. 

Amendment No. 1 
 to 

2017 Stock Incentive Plan 
 The
2017 Stock Incentive Plan (the “Plan”) of Torus Therapeutics. is hereby amended as follows (capitalized terms used herein and not defined herein shall have the respective meaning ascribed to such terms in the Plan): 

Section 4(a) shall be amended and restated in its entirety to read as follows: 
  

	“4.1	 Stock Available For Awards 

Subject to adjustment under Section 9, Awards may be made under the Plan for up to 8,000,000 shares of common stock, $0.0001 par value
per share, of the Company (the “Common Stock”), any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)). 

Except as aforesaid, the Plan shall remain in full force and effect. 

Adopted by the Board of Directors of the Company on 

October 17, 2017 and effective as the filing of the 

Certificate of Amendment of the Certificate of 

Incorporation of the Company on October 18, 2017. 

 Generation Bio Co. 

Amendment No. 2 
 to 

2017 Stock Incentive Plan 
 The
2017 Stock Incentive Plan (the “Plan”) of Generation Bio Co. is hereby amended as follows (capitalized terms used herein and not defined herein shall have the respective meaning ascribed to such terms in the Plan): 

Section 4(a) shall be amended and restated in its entirety to read as follows: 
  

	“4.1	 Stock Available For Awards 

Subject to adjustment under Section 9, Awards may be made under the Plan for up to 9,600,000 shares of common stock, $0.0001 par value
per share, of the Company (the “Common Stock”), any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)). 

Except as aforesaid, the Plan shall remain in full force and effect. 

Adopted by the Board of Directors of the Company on 

November 17, 2017 and effective as the filing of the 

Amended and Restated Certificate of Incorporation of the 

Company on November 17, 2017. 

 Generation Bio Co. 

Amendment No. 3 
 to 

2017 Stock Incentive Plan 
 The
2017 Stock Incentive Plan (the “Plan”) of Generation Bio Co. is hereby amended as follows (capitalized terms used herein and not defined herein shall have the respective meaning ascribed to such terms in the Plan): 

Section 4(a) shall be amended and restated in its entirety to read as follows: 
  

	“4.1	 Stock Available For Awards 

Subject to adjustment under Section 9, Awards may be made under the Plan for up to 13,100,000 shares of common stock, $0.0001 par value
per share, of the Company (the “Common Stock”), any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)). 

Except as aforesaid, the Plan shall remain in full force and effect. 

Adopted by the Board of Directors of the Company on 

February 16, 2018 and effective as the filing of the 

Amended and Restated Certificate of Incorporation of the 

Company on February 21, 2018. 

 Generation Bio Co. 

Amendment No. 4 
 to 

2017 Stock Incentive Plan 
 The
2017 Stock Incentive Plan (the “Plan”) of Generation Bio Co. is hereby amended as follows (capitalized terms used herein and not defined herein shall have the respective meaning ascribed to such terms in the Plan): 

The first sentence of Section 4(a) shall be amended and restated in its entirety to read as follows: 

“Subject to adjustment under Section 9, Awards may be made under the Plan for up to 14,850,000 shares of common stock, $0.0001 par
value per share, of the Company (the “Common Stock”), any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)).” 

Except as aforesaid, the Plan shall remain in full force and effect. 

Adopted by the Board of Directors of the Company on 

December 6, 2018 and effective as the filing of the 

Certificate of Amendment of the Amended and Restated 

Certificate of Incorporation of the Company on 

December 17, 2018. 

 Generation Bio Co. 

Amendment No. 5 
 to 

2017 Stock Incentive Plan 
 The
2017 Stock Incentive Plan (the “Plan”) of Generation Bio Co. is hereby amended as follows (capitalized terms used herein and not defined herein shall have the respective meaning ascribed to such terms in the Plan): 

The first sentence of Section 4(a) shall be amended and restated in its entirety to read as follows: 

“Subject to adjustment under Section 9, Awards may be made under the Plan for up to 18,150,000 shares of common stock, $0.0001 par
value per share, of the Company (the “Common Stock”), any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)).” 

Except as aforesaid, the Plan shall remain in full force and effect. 

Adopted by the Board of Directors of the Company on 

January 8, 2020 and effective as of the filing of the 

Certificate of Amendment of the Amended and Restated 

Certificate of Incorporation of the Company on January 9, 2020

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]